



CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

# DAILY EQUITY REPORT

---

## 25<sup>TH</sup> MARCH 2019



## INDIAN MARKET

INDICES	CLOSE	PREVIOUS
SENSEX	38164.61	38386.75
NIFTY	11456.90	11521.05

INDICES	CLOSE	PREVIOUS
NIKKEI	21627.34	21608.92
HANG SENG	29113.36	29071.56
KOSPI	2186.95	2184.88

## SECTORIAL INDICES

INDICES	CLOSE	CHANGE (%)
CNX 100	11613.55	-0.58
S&P CNX 500	9500.05	-0.55
CNX MIDCAP	4897.45	-0.75
CNX 200	5979.95	-0.58
BANK NIFTY	29582.50	-0.84

## TOP GAINERS

SCRIPT	CLOSE	CHANGE (%)
NTPC	134.10	3.75
LT	1,395.00	1.76
ASIANPAINT	1,471.20	1.03
JSWSTEEL	285.00	0.96

## TOP LOSERS

SCRIPT	CLOSE	CHANGE (%)
BPCL	377.00	-3.12
INFRA TEL	315.30	-3.00
TATAMOTOR	175.30	-2.72
HINDPETRO	268.20	-2.51

## INDIAN FACE



**INDIAN EQUITY BENCHMARK** - Benchmark indices ended lower but off day's low on Friday with Nifty finished below 11,500 level. At close, the Sensex was down 222.14 points at 38164.61, while Nifty was down 64.10 points at 11456.90. About 1009 shares have advanced, 1665 shares declined, and 143 shares are unchanged. NTPC, L&T, Asian Paints, JSW Steel and Hindalco Industries were top gainers on the Nifty, while losers were Bharti Infratel, BPCL, Tata Motors, HPCL and Reliance Industries. Except infra all other sectoral indices ended in red led by Nifty PSU bank, auto, energy, pharma, metal and IT. BSE Midcap fell 0.60 percent, while Smallcap index fell 0.40 percent.

## GLOBAL FACE



**Asian Market** - Asian markets finished higher today with shares in Hong Kong leading the region. The Hang Seng is up 0.14% while China's Shanghai Composite is up 0.09% and Japan's Nikkei 225 is up 0.09%.



**U.S. Market** - North and South American markets finished mixed as of the most recent closing prices. The S&P 500 gained 1.09% and the IPC rose 0.22%. The Bovespa lost 1.34%.



**European markets** - European markets are lower today with shares in France off the most. The CAC 40 is down 0.97% while London's FTSE 100 is off 0.86% and Germany's DAX is lower by 0.57%.

**MARKET MOVERS UPSIDE**

SCRIPT	CLOSE	CHANGE (%)
NTPC	134.10	3.75
INFY	745.00	0.82
COALINDIA	233.00	0.80
TATASTEEL	517.30	0.72

SCRIPT	CLOSE	CHANGE (%)
BPCL	377.00	-3.12
IOC	155.25	-2.36
RELIANCE	1345.10	-2.21
ZEEL	434.10	-2.05

**FII & DII ACTIVITY**

INSTITUTION	NET BUY (CR.)	NET SELL (CR.)
FII	7252.39	5480.78
DII	3319.03	4642.20

**NSE TOTALS**

INDICES	ADVANCES	DECLINES
NIFTY	19	31
BANK NIFTY	3	9

**NIFTY SPOT**

TREND				STRATEGY			
<b>BULLISH</b>				<b>BUY ON DIPS</b>			
PIVOT POINTS							
S3	S2	S1	P	R1	R2	R3	
11211	11349	11403	11488	11541	11626	11764	
S1-11304 S2-11229				R1-11621 R2-11763			



TREND				STRATEGY			
<b>BULLISH</b>				<b>BUY ON DIPS</b>			
PIVOT POINTS							
S3	S2	S1	P	R1	R2	R3	
28734	29254	29457	29774	29977	30294	30814	
BANK NIFTY		SUPPORT		RESISTANCE			
		S1-29450 S2-29254		R1-30000 R2-30300			



## MARKET TALKS



### Cadila says no observation by USFDA on Ahmedabad R&D facility

Shares of Cadila Healthcare slipped 2% in the last hour of the trading session on the BSE. "USFDA inspected the Pharmaceutical Technology Centre (PTC), the company's state-of-the-art R&D facility located at Ahmedabad, dedicated to new product development of various niche dosage forms including solid oral, parenteral, pulmonary, oncology, ointment & creams and transdermal, from March 18 to March 22, 2019," the company said in the BSE filing. At the end of the inspection, no observations (483) have been issued, the company added.



### Zydus gets final nod from USFDA for Lurasidone Hydrochloride tablets

Zydus Cadila has received the final approval from the USFDA to market Lurasidone Hydrochloride Tablets USP (US RLD - Latuda Tablets), in the strengths of 20 mg, 40 mg, 60 mg, 80 mg and 120 mg. It will be manufactured at the groups manufacturing facility at SEZ, Ahmedabad, as per BSE filing added. The medication is used to treat certain mental/mood disorders such as schizophrenia, depression associated with bipolar disorder. It may also help to decrease hallucinations (hearing/seeing things that are not there).



### Lupin launches generic Levothyroxine Sodium Tablets USP

Pharma major Lupin Limited (Lupin) announced the launch of Levothyroxine Sodium Tablets USP, having received approval from the USFDA earlier. Lupin's Levothyroxine Sodium Tablets USP, is the generic equivalent of AbbVie, Inc's Synthroid Tablets, as per BSE filing. It is indicated for: Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management.



### Tata Power SED bags contract from Ministry of Defence worth Rs1,200cr

Tata Power Strategic Engineering Division (Tata Power SED) announced the signing of an important deal with the Ministry of Defence, Government of India, to supply 23 ship-borne 3D Air Surveillance Radars to the Indian Navy over the next 10 years. The contract, estimated value is about Rs1200cr, was signed under the Buy & Make (India) category of the Defence Procurement Procedure (DPP) 2013 that will be offering the Indian Navy a proven solution, with a production arrangement in India under Transfer of Technology (ToT) and thereby furthering substantive self-reliance for India's defence requirements.

**NAME OF THE STOCK** : GODREJPROP  
**DATE** : 25/03/2019  
**SEGMENT** : CASH  
**CHART TYPE** : Candlestick  
**EXCHANGE** : NSE  
**TECHNICAL INDICATORS USED** : VOLUME.MACD,RSI.

**CHART****INVESTMENT ADVICE:**

**CALL CS CALL:- BUY GODREJPROP IN CASH ABOVE 847 TGT 864 SL 830**

**RATIONALE FOR ARRIVING INVESTMENT ADVICE :**

**TECHNICAL VIEW** : THE STOCK TECHINCALLY IS UP ,TAKING SUPPORT OF VOLUME.RESISTANCE IS BROKEN TODAY WITH HEAVY VOLUME.AS WELL AS A POSSIBILITY OF UPWARD MOVEMENT IS THERE.

**OTHER REASON IF ANY :-** SHOWING STRENGTHS IN INTRADAY CHARTS AS WELL.



## **DISCLAIMER**

The information and views in this report & all the service we provide are believed to be reliable, but we do not accept any responsibility for errors of fact or opinion. Investors have the right to choose the product/s that suits them the most. Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and up on sources that we consider reliable. This material is for personal information and based upon it & takes no responsibility. The information given herein should be treated as only factor, while making investment decision. The report does not provide individually tailor-made investment advice. My research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. Capitalstars shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of regulators. The price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for. Investment & Trading in Securities Markets are always subjected to market risk.

Capitalstars Financial Research Private Ltd., Reserves all Rights.

**INVESTMENT AND TRADING IN SECURITIES MARKET IS ALWAYS SUBJECTED TO MARKET RISK.**

## **BRANCH OFFICE**

**Capitalstars Financial Research Private Limited**

PLOT NO.32, MECHANIC NAGAR EXTENSION,IDA SCHEME

NO.54,VIJAYNAGAR INDORE

## **REGISTERED OFFICE**

PLOT NO.12, SCHEME NO.78 PART-2, VIJAY NAGAR, INDORE

Email:-[backoffice@capitalstars.in](mailto:backoffice@capitalstars.in)

Contact us :- [9977499927, 9039012727](tel:9977499927)

**Report Is Checked by Investment Advisor:**